Acute lymphoblastic leukemia (ALL) has been a major area of focus for multispecific antibody development due to the consistent expression of tumor-associated antigens such as CD19 and CD22 on B-lineage blasts. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.